Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.80
0.0%
$21.95
$16.97
$28.35
$3.75B0.861.71 million shs173,259 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$4.60
-3.0%
$3.39
$1.95
$4.99
$1.18B0.621.68 million shs355,169 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.30
-4.9%
$9.32
$6.28
$18.49
$3.49B0.08227,796 shs60,308 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$55.30
-1.6%
$51.35
$23.30
$66.06
$3.44B2.221.33 million shs173,797 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-2.68%-0.68%+0.28%-3.96%+25.00%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-2.27%+27.08%+54.40%+51.92%+138.19%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+1.40%-3.82%+2.75%+49.59%-36.96%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.13%-6.94%+17.32%+14.57%+82.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.80
0.0%
$21.95
$16.97
$28.35
$3.75B0.861.71 million shs173,259 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$4.60
-3.0%
$3.39
$1.95
$4.99
$1.18B0.621.68 million shs355,169 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.30
-4.9%
$9.32
$6.28
$18.49
$3.49B0.08227,796 shs60,308 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$55.30
-1.6%
$51.35
$23.30
$66.06
$3.44B2.221.33 million shs173,797 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-2.68%-0.68%+0.28%-3.96%+25.00%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-2.27%+27.08%+54.40%+51.92%+138.19%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
+1.40%-3.82%+2.75%+49.59%-36.96%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.13%-6.94%+17.32%+14.57%+82.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.75
Moderate Buy$31.0042.23% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.50
Moderate Buy$5.7023.91% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.78
Moderate Buy$21.13105.12% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.572.30% Upside

Current Analyst Ratings Breakdown

Latest MRVI, TLX, ACAD, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Reiterated RatingBuy$6.00
5/8/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetBuy$33.00 ➝ $32.00
5/8/2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Boost Price TargetOverweight$4.50 ➝ $5.50
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
5/1/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
DowngradeHold (C+)Hold (C)
4/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Reiterated RatingSell (D)
4/14/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$50.00 ➝ $55.00
4/13/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Reiterated RatingOutperform$22.00
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B3.48$0.86 per share25.25$7.25 per share3.01
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$185.74M6.37$0.40 per share11.59$1.46 per share3.15
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.35$0.04 per share253.30$1.23 per share8.37
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M9.14N/AN/A$7.84 per share7.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.209.9625.6425.1634.30%9.61%7.07%N/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$130.77M-$0.71N/AN/AN/A-51.07%-17.29%-8.74%N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A60.58N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A

Latest MRVI, TLX, ACAD, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.05$0.01+$0.06-$0.02$53.00 million$65.84 million
5/6/2026Q1 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.04$0.02-$0.02$0.02$280.25 million$268.10 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
2/26/2026Q4 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.12$1.60+$1.48$1.60$292.54 million$298.00 million
2/25/2026Q4 2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.07-$0.04+$0.03-$0.24$49.06 million$49.87 million
2/20/2026H2 2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$0.0493-$0.01-$0.0593-$0.0070$421.50 million$206.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.59
3.48
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.85
6.60
5.69
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.08
1.43
1.27
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510171.24 million126.37 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610257.07 million250.67 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.11 millionN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.80 -0.01 (-0.02%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$4.60 -0.14 (-2.95%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.30 -0.53 (-4.90%)
As of 11:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$55.30 -0.91 (-1.62%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.